Development of Capecitabine Floating Tablet Dosage Forms for Treating Stomach Cancer
Abstract
Objective: In the present research work, oral gastro retentive dosage forms (GRDFs) of capecitabine (CPC) were formulated using floating concept.
Methods: GRDFs were formulated using hydroxypropyl methyl cellulose (HPMC K4M and K15M) as drug release retardant, sodium bicarbonate (NaHCO3) and calcium carbonate (CaCO3) as gas generating agents, and micro crystalline cellulose (MCC), dicalcium phosphate (DCP), spray dried lactose (SDL), and pre gelatinized starch (PGS) as fillers. The tablets were prepared by direct compression method and evaluated for various parameters. The GRDFs were also characterized by Fourier-transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC).
Results and Discussion: All the formulations were subjected for pre and post compression parameters, shows all the data within the limits. The lag times of GRDFs has decreased significantly for formulations containing calcium carbonate when compared to sodium bicarbonate as gas generating agent. In vitro drug release studies indicate that higher polymer concentration delayed the CPC release, and the sustaining effect was in the order K4M > K15M > LVCR 100. Addition of MCC, DCP, SDL, and PGS as fillers further affected the lag time and in turn the CPC release rates.
Conclusion: The formulation (F9) containing 10%w/w HPMC K4M as the release retardant, microcrystalline cellulose as filler and 20%w/w CaCO3 as gas generating agent fulfilled regulatory requirements in terms of percent drug release at the end of 24h.
Keywords: Capecitabine, Gastro retentive floating tablets, floating drug delivery systems, FTIR, DSC.
Keywords:
Capecitabine, Gastro retentive floating tablets, floating drug delivery systems, FTIR, DSCDOI
https://doi.org/10.22270/jddt.v10i3-s.4171References
Parkin M, Freddie B, Ferlay J, Pisani P. Global Cancer Statistics – 2002. CA Cancer Journal for Physicians. 2005; 55(2):74-108.
Kamangar F, Dores GM, Anderson WF. Patterns of Cancer Incidence, Mortality and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. Journal of clinical oncology. 2006; 24(14):2137-50.
Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y. Comparative Studies on the Immunosuppressive Effect among 5-deoxy-5-fluorouridine, ftorafur and 5-fluorouracil. Japanese Journal of Cancer Research. 1980; 71:190-196.
Ninomiya Y, Miwa M, Eda H, Sahara H, Fujimoto K, Ishida M, Umeda I, Yokose K, Ishitsuka H. Comparative Antitumor Activity and Intestinal Toxicity of 5-deoxy-5- fluorouridine and its Prodrug Trimethoxybenzoyl-5-deoxy-5-fluorocytidine. Japanese Journal of Cancer Research. 1990; 81:188-195.
Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive Correlation between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts. Cancer Research. 1998; 58:685–690.
Ishitsuka H. Capecitabine: Preclinical Pharmacology Studies. Investigational New Drugs. 2000; 18(4):343-354.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo H. Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine by Taxol/Taxotere in Human Cancer Xenografts. Clinical Cancer Research. 1998; 4(4):1013-1019.
Fujimoto ouchi K, Sekiguchi F, Moriya Y, Mori K, Tanaka Y. Antitumor Activity of Transtuzumab in Combination with Chemotherapy in Human Gastric Cancer Xenograft Models. Cancer Chemotherapy Pharmacology. 2007; 59(6):795-805.
Reigner B, Blesch K, Weidekamm E. Cinical Pharmacokinetics of Capecitabine. Clinical Pharmacokinetics. 2001; 40(2):85-104.
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a Novel Oral Fluoropyrimidinecarbamate, Capecitabine Which Generates 5-Fluorouracil Selectively in Tumours by Enzymes Concentrated in Human Liver and Cancer Tissue. European Journal of Cancer. 1998; 34:1274-1281.
Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, Bosron WF. Hydrolysis of Capecitabine to 5’-deoxy-5-fluorocytidinebyhuman Carboxylesterases and Inhibition by Loperamide. The Journal of Pharmacology and Experimental Therapeutics. 2005; 313(3):1011-1016.
The United States Pharmacopoeia. National formulary. Vol. 1. Asian edition. Rockville (MD): United State Pharmacopoeial Convention Inc; 2007. Capecetibine; P. 643-645.
Lachman L, Lieberman HA, Joseph LK. The theory and practice of industrial pharmacy. 3rd ed. Mumbai: Varghese publishing house; 1987. P. 296-300.
Lapidus H, Lordi NG. Drug Release from Compressed Hydrophilic Matrices. Journal of Pharmaceutical Sciences. 1966; 55: 840-843.
Higuchi T. Mechanism of Sustained Action Medication, Theoretical Analysis of Rate of Solid Drugs Dispersed in Solid Matrices. Journal of Pharmaceutical Sciences. 1963; 52:1145-1148.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of Solute Release from Hydrophilic Polymers. International Journal of Pharmaceutics. 1983; 15:25-35.
O’Neil, M.J., ed. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th ed. New jersey: Merck, 2001.
Food and Drug Administration, Centre for Drug Evaluation and Research. Guidance- Dissolution testing of Extended Release Solid Oral Dosage forms. 1997.
Published
Abstract Display: 697 
PDF Downloads: 766 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.